50 of the Top 250 law firms use our Products every day
Confidential Treatment
Requested. Confidential portions of this document have been
redacted and separately filed with the
Commission.
THIRD EXTENSION
AGREEMENT
Between
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
of P.O. Box 95, Rehovot 76100,
Israel
(hereinafter
“Yeda”)
and
XTL BIOPHARMACEUTICALS
LTD.
of Kiryat
Weizmann
PO Box
370
Rehovot 76100,
Israel
(hereinafter “the
Company”)
|
WHEREAS
|
Yeda and the
Company have entered into a Research and Licence Agreement dated
April 7, 1993 (hereinafter “the Main Agreement”) which
was extended in an Amendment of the Research and Licence Agreement
on August 31, 1995 (hereinafter “the Amendment
Agreement”) and in the Second Extension Agreement on August
12, 1996 (“the Second Extension Agreement”);
and
|
|
WHEREAS
|
Yeda and the
Company desire to further extend the Research Period and agree to
the 1998 Budget and the 1998 Research Plan (as these terms are
hereinafter defined) for said period;
|
NOW THEREFORE
IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS:
|
|
The Appendix
listed below which is attached hereto shall constitute an integral
part hereof:
|
Appendix 1 - the 1998 Research Programme and
Budget
|
2.1.
|
“Yeda” shall mean Yeda Research and
Development Co. Ltd. of P.O. Box 95, Rehovot 76100,
Israel.
|
|
2.2.
|
“The
Company” shall mean XTL Biopharmaceuticals Ltd., of Kiryat
Weizmann, P.O. Box 370, Rehovot 76100, Israel.
|
|
2.3.
|
“The Main
Agreement” shall mean the Research and Licence Agreement
between Yeda and the Company, dated April 7, 1993.
|
|
2.4.
|
“The
Amendment Agreement” shall mean the Amendment of Research and
Licence Agreement dated August 31, 1995.
|
|
2.5.
|
“The
Second Extension Agreement” shall mean the agreement
extending the Research Period untill August 31, 1997.
|
|
2.6.
|
“The 1998
Research” shall mean the Research contemplated under the 1998
Research Programme. The term “Research” in the Main
Agreement shall be deemed to
|
|
